MétaCan
Menu
Back to cohort

Abstract FO01-01: Global impact of HPV vaccination

2013· article· en· W2520929624 on OpenAlexaboutno aff
Anna R. Giuliano

Bibliographic record

VenueCancer Prevention Research · 2013
Typearticle
Languageen
FieldMedicine
TopicCervical Cancer and HPV Research
Canadian institutionsnot available
Fundersnot available
KeywordsGenital wartsMedicineCervical cancerHPV vaccinesPopulationIncidence (geometry)VaccinationHPV infectionVaccine efficacyPublic healthDeveloped countryDemographyGynecologyEnvironmental healthCancerImmunologyInternal medicine

Abstract

fetched live from OpenAlex

Abstract HPV causes multiple cancers in men and women, accounting for ~5% of all cancers worldwide. In 2006 a 4-valent HPV vaccine was licensed for use for cervical cancer prevention in the US and other countries. After completion of a male HPV vaccine efficacy trial, the 4-valent HPV vaccine was also licensed for the prevention of genital warts in 2009 and anal cancer in 2010. Since licensure, several countries have developed policies promoting national dissemination of the vaccine. Australia has led the way with a robust public health program that rapidly reached ~80% of the age eligible female population. With up to six full years of vaccine dissemination to adolescent females countries are now able to report population effectiveness, or the impact of the vaccine to prevent HPV-related diseases. There are three main outcome variables of interest: short-term (HPV infection and genital wart rates), intermediate-term (reduction in incident cervical lesions), and long-term (incidence and mortality from HPV-related cancers). Effectiveness data for short-term outcomes have recently been reported for Australia, New Zealand, Denmark, Sweden, Germany, Belgium, Canada, and the US. Significant declines in genital wart incidence in females have been reported from all countries to date that have evaluated effectiveness. In Australia, where there was early vaccine adoption nationally and high vaccine penetrance, concomitant declines in genital warts among unvaccinated males have also been documented. Intermediate-term endpoints, such as cervical pre-cancerous lesions have also significantly declined in Australia, Denmark, and the US. These results provide early evidence that routine vaccination significantly reduces HPV infection and early disease endpoints attributed to the 4 major disease causing types of HPV among young adult females at the population level. However, to achieve the full promise of eliminating HPV vaccine type-related disease, broad dissemination of the vaccine is required. Several strategies are under consideration to improve population coverage, including dissemination of vaccine to low resource countries through the GAVI program, alternative dose schedules, and two vs. three dose schedules. Ultimately, strong public health and physician recommendations, as well as population acceptability, are needed to eliminate HPV-related disease through a vaccine approach. Citation Format: Anna R. Giuliano. Global impact of HPV vaccination. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr FO01-01.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.946
Threshold uncertainty score0.902

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.2530.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.126
GPT teacher head0.532
Teacher spread0.406 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2013
Admission routes1
Has abstractyes

Explore more

Same venueCancer Prevention ResearchSame topicCervical Cancer and HPV ResearchFrench-language works237,207